Dose-dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pylori-positive patients.

ABSTRACT:

Background

Gastric intestinal metaplasia is a pre-cancerous condition associated with multiple factors.

Objective

We evaluated whether cumulative proton pump inhibitor dose is associated with the diagnosis of gastric intestinal metaplasia while controlling for multiple variables.

Methods

We retrospectively identified patients who underwent upper endoscopy with gastric biopsy between 2005 and 2014. Covariate data retrieved included age, sex, ethnicity, smoking status, Helicobacter pylori status (based on clarithromycin-amoxicillin-proton pump inhibitor issued), cumulative proton pump inhibitor issued within 10 years (quartiles [PPI-Q_1-4 ] of daily drug dose), anti-parietal cell antibodies, body mass index and comorbidity index.

Results

Of the 14,147 i

SUBMITTER: Snir Y 

PROVIDER: S-EPMC8259238 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature